Delving into the Latest Updates on Hydroxyethyl Starch with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

hydroxyethyl starch, 羟乙基淀粉130/0.4氯化钠注射液, Bolben infusion 6%

+ [7]

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Hypovolemia

Inactive Indication

Massive hemorrhageShock, Septic

Originator Organization

Fresenius Kabi AG

Active Organization

Fresenius Kabi AGFresenius Kabi Deutschland GmbHFresenius Kabi Australia Pty Ltd.

Inactive Organization

B. Braun Melsungen AG

Novo Nordisk A/SFresenius Kabi Japan KK

License Organization-

Drug Highest PhaseApproved

First Approval Date

Germany (25 Apr 2000)

Regulation-

Login to view timeline

The investigators propose a multicenter randomized trial to test the renal safety of 6% hydroxyethyl starch (HES) 130/0.4 combined with sodium acetate Ringer's crystalloid solution in moderate-to-high cardiovascular risk patients having major abdominal surgery. The reference group will only be given sodium acetate Ringer's crystalloid.

Start Date30 Nov 2024

Sponsor / Collaborator

Xiangya Hospital Central South University

CTRI/2024/11/076968

/ Not yet recruitingNot ApplicableIIT

Fluid management in head and neck oncosurgery with flap reconstruction: a comparison between crystalloid with Hydroxy ethyl starch vs crystalloid with Gelatin and its effect on patient’s haemodynamics and flap viability: a prospective observational study - Nil

Start Date25 Nov 2024

Sponsor / Collaborator-

CTRI/2024/10/075715

/ Not yet recruitingPhase 4IIT

Pretreatment with 6% Hydroxyethyl starch for reduction of propofol injection pain : A prospective randomized controlled study - NIL

Start Date19 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Hydroxyethyl Starch

Login to view more data

100 Translational Medicine associated with Hydroxyethyl Starch

Login to view more data

100 Patents (Medical) associated with Hydroxyethyl Starch

Login to view more data

2,525

Literatures (Medical) associated with Hydroxyethyl Starch

31 Dec 2025·Future Science OA

Hesperidin alleviates pulmonary fibrosis by regulating EI24-mediated autophagy

Article

Author: Zhang, Yan ; Wan, Fang ; Ma, Wen

BACKGROUNDEtoposide-induced protein 2.4 (EI24), an essential component of autophagy, is lowly expressed in pulmonary fibrosis. Hesperidin (Hes), a flavonoid, can regulate autophagy in various diseases. However, whether Hes can inhibit pulmonary fibrosis by mechanically regulating EI24-mediated autophagy has not been uncovered.METHODSRLE-6TN cells were treated with transforming growth factor β1 (TGF-β1) and rats were injected with bleomycin (BLM) to construct the pulmonary fibrosis model. The effect of Hes on pulmonary fibrosis was evaluated by cell counting kit-8, immunofluorescence, hematoxylin and eosin, masson trichome staining and western blotting.RESULTSHes reduced cell viability of TGF-β1-induced RLE-6TN cells. Administration of Hes restored the decrease in autophagy marker levels in TGF-β1-induced RLE-6TN cells. Hes inhibited the transcriptional and translational levels of α-SMA, collagen I and fibronectin that were increased by TGF-β1 in RLE-6TN cells. Mechanically, Hes restored EI24 expression, and EI24 knockdown reversed the effect of Hes on the expressions of autophagy and fibrosis-related proteins. Additionally, Hes enhanced autophagy and fibrosis markers, which were worsened by EI24 knockdown in BLM-induced rats.CONCLUSIONHes activated autophagy by upregulating EI24, which improved pulmonary fibrosis both in vitro and in vivo.

01 Jun 2025·International Journal of Pharmaceutics: X

Fucoidan/Polyvinylpyrrolidone/Hesperitin nanoparticle complex for corneal injury treatment: Synthesis, characterization, and therapeutic efficacy

Article

Author: Wu, Xiaochen ; Zhang, Zhengpei ; Liu, Yalu ; Li, Jie ; Ge, Xing ; Liu, Haiyang ; Guan, Lina

Corneal injury is a common ailment that, if not addressed promptly and efficiently, has the potential to result in significant visual impairment. This study investigates the therapeutic potential of a novel FU/PVP/Hes nanoparticle complex composed of fucoidan (FU), polyvinylpyrrolidone (PVP), and hesperitin (Hes) for corneal injury treatment. The FU/PVP/Hes nanoparticles were synthesized using a solvent evaporation method and characterized for their morphology, size distribution, biocompatibility, antioxidant activity, and anti-inflammatory capacity. The nanoparticles demonstrated excellent biocompatibility with low hemolysis rates and minimal cytotoxicity. They also exhibited potent antioxidant and anti-inflammatory properties, which were attributed to the enhanced solubility and bioavailability of Hes through nanoparticle formation. In vivo investigations employing a mouse model of corneal injury induced by alkali burns showed that the FU/PVP/Hes nanoparticles significantly promoted corneal epithelial healing, reduced corneal opacity, and suppressed the elevation of inflammatory cytokines. Histopathological analysis confirmed the nanoparticles' ability to facilitate corneal tissue repair. The study concludes that the FU/PVP/Hes nanoparticle complex is a promising therapeutic agent for corneal injury treatment due to its biocompatibility and multifaceted therapeutic effects.

01 May 2025·International Journal of Biological Macromolecules

Hyaluronic acid-based hesperidin nanostructured lipid carriers loaded dissolving microneedles: A localized delivery approach loaded for the management of obesity

Article

Author: Gopan, Gopika ; Khot, Kartik Bhairu ; Jose, Jobin ; Deshpande N, Shridhar ; Bandiwadekar, Akshay

Obesity, a persistent imbalance of calories, has become one of the major clinical factors that result in many metabolic disorders. Despite excellent anti-obesity properties, the poor aqueous solubility of hesperidin (HES), a flavonoid, hampers its applicability. To resolve this issue and conquer oral administration's drawbacks, our study has concentrated on encapsulating HES in nanostructured lipid carriers (NLCs) and incorporating the NLCs into microneedles (MNs). By developing HES-loaded NLCs (HES-NLCs) with hyaluronic acid (HA) as a base design to form a microneedle patch (HES-NLCMNP), the study aimed to increase the stability and bioavailability of HES and provide an innovative way for the management of obesity. HES-NLCs were loaded to the microneedle, to promote anti-obesity activity. The microneedle tip, which has been composed of HA, will act as a biodegradable polymer that could effectively deliver the activity of HES-NLC to the blood stream. Furthermore, the base of the microneedle patch composed of polyvinyl alcohol (PVA) offered excellent flexibility, releasing HES and providing resistance to any adverse effects. Analysis revealed that the prepared HES-NLCs have desirable physical characteristics with an extended-release profile. The optimised NLC formulation (F₃F) was later incorporated into HA-base-designed MNs that demonstrated mechanical solid integrity and effective skin penetration. In vivo pharmacokinetics significantly improved all parameters with a reduced elimination rate. Physiological, haematological, and antioxidant markers improved in treated rats, with histopathological analysis showing significant tissue alterations. The results suggest that HES-NLCMNP is a promising platform to improve drug effectiveness, patient compliance, and treatment outcomes for obesity.

100 Deals associated with Hydroxyethyl Starch

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B05AA07	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypovolemia	Australia	Fresenius Kabi Australia Pty Ltd.	13 Nov 2006

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Massive hemorrhage	Phase 2	Japan	Fresenius Kabi Japan KK	01 May 2010
Hypovolemia	Phase 2	Japan	Fresenius Kabi Japan KK	01 Nov 2009
Shock, Septic	Phase 2	Germany	Novo Nordisk A/S	01 Apr 2003
Shock, Septic	Phase 2	Germany	B. Braun Melsungen AG	01 Apr 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02192502 (SHARP, CTgov)	Phase 3	-	149	HES 130/0.4 (Voluven) (HES 130/0.4 (Voluven))	mgsnwtvezs(dzadpczdqh) = kcxpaprcqv kviejisaji (vkyogepcce, qpvluywwgv - oqniypqijn) View more	-	14 Feb 2023
				human albumin 5% (Human Albumin 5%)	mgsnwtvezs(dzadpczdqh) = rkgjmtxtvx kviejisaji (vkyogepcce, ntmecuyxxu - ydqogjujid) View more
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	ekzhtjpmzn(lhxyzlkggk) = svbdzvkefz ianrxvxvhn (byeureupcn, nbeukvprkh - fekyvaxbob) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	ekzhtjpmzn(lhxyzlkggk) = gvpompvbqi ianrxvxvhn (byeureupcn, vtgotaqmcs - evhfkuptfn) View more
NCT01195025 (Pubmed \| Crit Care)	Not Applicable	Hypovolemia	10	6% hydroxyethyl starch 130/0.4 (Voluven™)	vyeczvvose(nxtzidkosh) = dhvfnztiqw ynqivmxrfx (nacvqexzbn ) View more	-	29 May 2013
				Ringer's acetate	(ldnlojwcsy) = uoyglfuqgp ylppbrzutw (vlfnjnsaah )